AIMS Cancer Outcomes Study
Recruiting now
Conditions studied: Neoplasms, Neoplasm Malignant, Advanced Cancer, Advanced Solid Tumor, Oncology
In brief
The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect data and study outcomes for patients with cancer who receive care at AIMS Institute.
Key facts
- Study ID
- NCT04495790
- Run by
- Advanced Integrative Medical Science Institute
- People needed
- 500
- Starts
- 2020-05-18
- Expected to finish
- 2030-12-31
- Last updated by the study team
- 2023-02-01
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- A new patient coming in for a first office call (FOC) or first consultation via telemedicine with a diagnosis of cancer, or
- An established patient with a diagnosis of cancer receiving treatment at the AIMS Institute;
- If over 18 years of age are able to understand study design adequately and provide signed informed consent (IC) to enrollment;
- If younger than 18 years of age informed assent from the child and informed consent from a parent or guardian who is able to understand the study design adequately and provide signed informed consent for the pediatric patient;
- A confirmed diagnosis of cancer based on medical oncology medical records.
You may not qualify if…
- Patients not diagnosed with cancer;
- Telehealth patients;
- Cannot read or understand English well enough to read and sign the consent form and complete the questionnaires;
- Unwilling to participate in the AIMS Institute observational study.
Where it is running
- AIMS Institute — Seattle, Washington, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.